|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Human granulocyte-macrophage colony-stimulating factor (GM-CSF) was purified from 3 liters of serum-free conditioned medium of the Hodgkin's tumor cell line L428 KSA.
|
3539201 |
1986 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Southern blot analysis of each tumor DNA showed no gross rearrangement of the GM-CSF gene.
|
3119535 |
1987 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Interestingly, granulocyte-macrophage colony-stimulating factor (GM-CSF) mRNA was concomitantly expressed in most of these G-CSF-producing tumors.
|
1701653 |
1990 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Frequent expression of receptors for granulocyte-macrophage colony-stimulating factor on human nonhematopoietic tumor cell lines.
|
2162848 |
1990 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
IL-2-expanded 444P.3 cells, tested on day 104 in culture, expressed mRNA for tumor necrosis factor (TNF), IL-2 and tumor growth factor beta (TGF-beta) but not for IL-1, lymphotoxin or granulocyte/macrophage-colony stimulating factor (GM-CSF).
|
1968360 |
1990 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
However, there is no evidence for GM-CSF production by glioblastoma cells in vivo: fresh tumor samples lack the mRNA for GM-CSF and the protein is not detectable in the tumor cyst fluids or the cerebrospinal fluids of glioblastoma patients.
|
1315829 |
1992 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
It is thought that the production of colony-stimulating factor by neoplasms is the most potent cause of tumour-induced leukocytosis; several mechanisms have been suggested to explain this.
|
7691144 |
1993 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
(c) Some, but not all, lung carcinomas produced this cytokine, and a close correlation was found between the production of GM-CSF and the number of CD1a+ LC infiltrating these tumors.
|
7679411 |
1993 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Thus gross structural lesions in the genes encoding the GM-CSF receptor alpha and beta chains appear to be infrequent in hemopoietic neoplasms.
|
8418381 |
1993 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Using the retroviral vector MFG in conjunction with short-term culture techniques, we have achieved, in the absence of selection, a mean transduction efficiency of 60% in primary renal, ovarian, and pancreatic tumor explants, and we have developed an autologous granulocyte-macrophage colony-stimulating factor secreting tumor vaccine for clinical trials.
|
8485707 |
1993 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Granulocyte-macrophage colony stimulating factor secreting tumor cell preparations were less effective, and interferon-gamma secreting cells had only a marginal effect.
|
8137291 |
1994 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Production of granulocyte-macrophage colony-stimulating factor (GM-CSF) by murine tumors has been shown to induce immune suppressive cells having homology with GM progenitor cells.
|
9815891 |
1995 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
However, they allow us to suggest a possible metastatic tumour cell phenotype, in which autogenous GM-CSF expression could modulate immune response against the tumour cell itself or could potentiate metastatic colonization properties.
|
7734955 |
1995 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Expression of GM-CSF was detected in 7 (58%) of 12 tumors, IL-10 was found in 3 (25%) and IFN-gamma in 6 (50%) of the samples.
|
8820364 |
1996 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Studies employing rodent tumor models with little or no intrinsic immunogenicity have shown that genetically modified tumor cell preparations consisting of irradiated tumor cells transduced with and expressing cytokines, such as interleukin-2 (IL-2), IL-6, interferon-gamma (IFNgamma), or granulocyte-macrophage colony stimulating factor (GM-CSF), or co-stimulatory molecules, such as B7-I, were capable of inducing the regression of preexisting tumors and cure animals from their disease.
|
8607020 |
1996 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The antitumor efficacy of this nonviral approach was tested using irradiated B16 tumor cells that were transfected with mGM-CSF cDNA and injected into mice as tumor "vaccine".
|
8864754 |
1996 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The TIL cell line PM2-B2 did not lyse, but instead released granulocyte-macrophage colony-stimulating factor in response to the autologous tumor or HLA-A1-matched allogeneic tumor cell lines.
|
9816095 |
1996 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We assessed TIL expression of interleukin-2 (IL-2), IL-4, tumor necrosis factor-alpha (TNF-alpha), interferon-gamma (IFN-gamma), granulocyte-macrophage colony stimulating factor (GM-CSF), IL-10, and transforming growth factor-beta (TGF-beta), and tumor cell expression of IL-10 and TGF-beta in situ in 49 primary colon carcinomas and 20 metastases using immunohistochemistry.
|
8826937 |
1996 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Tumor vaccination with macrophage colony-stimulating factor-producing Lewis lung carcinoma in mice.
|
8704254 |
1996 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Granulocyte-macrophage colony-stimulating factor (GM-CSF) gene-transduced, irradiated tumor vaccines induce potent, T-cell-mediated antitumor immune responses in preclinical models.
|
9108457 |
1997 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Chimeric CLL-1 antibody fusion proteins containing granulocyte-macrophage colony-stimulating factor or interleukin-2 with specificity for B-cell malignancies exhibit enhanced effector functions while retaining tumor targeting properties.
|
9192768 |
1997 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
This sequence, named the A element, has an active role on GM-CSF transcription and is responsive to the tumor promoter PMA in transient transfection experiments.
|
9414129 |
1997 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Thus, this study illustrates a potential gene therapy strategy for glioblastoma multiforme patients using GM-CSF and/or B7-2 transduced tumor vaccines.
|
9189765 |
1997 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Ongoing human tumor immunotherapy studies use patients' melanoma or renal carcinoma cells transfected with a retroviral vector containing GM-CSF cDNA as a vaccine to elicit anti-tumor immune responses.
|
9143914 |
1997 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Together, our results demonstrate an antagonistic effect of IL-10 with respect to GM-CSF-induced DC accumulation and tumor immunity and suggest a new mechanism by which tumors escape immune recognition: namely by preventing APC from obtaining access to tumor Ags.
|
9218594 |
1997 |